Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for DHR and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for DHR and 80,000+ other tickers.
See exactly how DHR's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for DHR and 80,000+ other tickers.
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics…
HB Wealth Management LLC cut its position in Danaher Corporation (NYSE: DHR) by 13.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,772 shares of the conglomerate's stock after selling 7,499 shares during the period. HB Wealth Management LLC's
Healthcare is moving away from the traditional model of mass-produced, one-size-fits-all treatments toward individualized therapies. This evolution in medicine aims to provide treatments that are not only more effective but also carry a lower risk of adverse side effects by aligning with a patient's unique biology.
Ausdal Financial Partners Inc. purchased a new position in Danaher Corporation (NYSE: DHR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 2,452 shares of the conglomerate's stock, valued at approximately $467,000. Several other institutional investors and hedge funds have also
Bamco Inc. NY purchased a new stake in shares of Danaher Corporation (NYSE: DHR) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 315,789 shares of the conglomerate's stock, valued at approximately $227,381,000. Several other hedge funds have also bought and sold shares
DHR's Biotechnology segment grows as China demand, bioprocessing and improving discovery markets offset regional headwinds.